About BRD4 Inhibitor-27
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Key demo objectives ended up to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymy